Apogee Therapeutics recently released its 10-Q report. Apogee Therapeutics, Inc. is a clinical-stage biotechnology company developing antibody-based therapies for inflammatory and immunology diseases, including atopic dermatitis, asthma, eosinophilic esophagitis and chronic obstructive pulmonary disease. Its pipeline includes zumilokibart (APG777), APG279, APG273 and APG808, and the company was incorporated in 2022 and is based in Waltham, Massachusetts.
In Item 2, Management’s Discussion and Analysis, Apogee said it is advancing multiple programs built around optimized biologics and antibody engineering, with zumilokibart as its lead asset. The company said APG777 is in Phase 2 testing for atopic dermatitis and in Phase 1 testing for asthma and eosinophilic esophagitis; APG279 is in Phase 1 for atopic dermatitis; APG273 is in Phase 1 for asthma and COPD; and APG808 targets IL-4Ra for type 2 allergic diseases.
Apogee’s discussion centered on clinical progress and the timing of upcoming readouts. For the APEX Phase 2 atopic dermatitis trial, Part A enrolled 123 adults and tested a 720 mg induction regimen at Weeks 0 and 2, followed by 360 mg at Weeks 4 and 12; the company said it reported 16-week data in July 2025 and 52-week maintenance data in March 2026. In Part A, 66.9% of patients on zumilokibart reached EASI-75 versus 24.6% on placebo, 34.9% achieved vIGA 0/1 versus 17.3% on placebo, and 33.9% reached EASI-90 versus 14.7% on placebo.
The company also said Part B of APEX began dosing in February 2025 and finished enrollment in January 2026 with 347 patients, ahead of schedule. Apogee expects 16-week topline induction data from Part B in the second quarter of 2026 and, if results and FDA alignment are favorable, Phase 3 trials in atopic dermatitis in the second half of 2026.
In asthma, Apogee said it started a Phase 1b trial in April 2025 and reported interim data in January 2026. The study enrolled 31 adults, with 19 meeting the prespecified Type 2 inflammation analysis population; in that group, the company said a single 720 mg dose produced a maximum absolute mean FeNO reduction of 45 ppb, or 60% from baseline, with suppression lasting through 16 weeks and through 32 weeks in the small number of patients with longer follow-up.
Apogee said the asthma data, together with the APEX Part B results, will help determine dose selections for expansion programs in 2027 and beyond. The company said it expects to announce plans for the Phase 2 ASPIRE asthma trial and the Phase 2 ELEVATE eosinophilic esophagitis trial in the second half of 2026, while also considering additional indications such as alopecia areata, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and prurigo nodularis. Following these announcements, the company's shares moved 6.06%, and are now trading at a price of $88.06. For the full picture, make sure to review Apogee Therapeutics's 10-Q report.
